Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey

scientific article published in January 2003

Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S10120-003-0216-9
P698PubMed publication ID12775015
P5875ResearchGate publication ID10735844

P50authorToshihiko DoiQ80212852
Narikazu BokuQ88572199
Atsushi OhtsuQ115365827
P2093author name stringManabu Muto
Shigeaki Yoshida
Tomonori Yano
Yasuo Hamamoto
Hiroki Kawai
Yasushi Sano
Fumio Nagashima
Kiyomi Mera
P2860cites workPhase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancerQ28361226
Late phase II study of S-1 in patients with advanced head and neck cancerQ33339533
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerQ33488159
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancerQ34366342
Long-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trialsQ34620968
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study GroupQ36621749
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).Q40613157
Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practiceQ43835909
Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective studyQ43887008
Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.Q53667890
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsQ71665880
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study GroupQ73676552
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patientsQ77809280
P304page(s)19-23
P577publication date2003-01-01
P1433published inGastric CancerQ15724608
P1476titleEfficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey
P478volume6 Suppl 1

Reverse relations

cites work (P2860)
Q37042302Advanced gastric cancer showing long-term complete remission in response to S-1 monotherapy: two case reports
Q98288637Clinical Complete Response after Chemotherapy and Palliative Surgery for Unresectable Gastric Cancer
Q83969769Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy
Q41907282S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer.
Q36403318Tolerability of adjuvant chemotherapy with S-1 after curative resection in patients with stage II/III gastric cancer.

Search more.